<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04214990</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2019-0184</org_study_id>
    <nct_id>NCT04214990</nct_id>
  </id_info>
  <brief_title>Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients</brief_title>
  <official_title>Effect of Aspirin for the Gastric Cancer Prevention in Early Gastric Cancer Patients Who Underwent Endoscopic Resection: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incheon St.Mary's Hospital/The Catholic University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kosin University Gospel Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chilgok Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to investigate the effect of low-dose (100 mg) asprin on the prevention of
      gastric cancer in the early gastric cancer patients with negative H. pylori status who
      underwent endoscopic submucosal dissection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aspirin has been widely used as an anti-platelet drug for the primary or secondary prevention
      of cardiovascular events, including ischemic heart disease and stroke. In 2016, the U.S.
      Preventive Services Task Force recommended initiating low-dose aspirin use for the primary
      prevention of cardiovascular diseases and colorectal cancer in adult aged 50 to 59 years who
      have a 10% or greater 10-year cardiovascular disease risk, are not at increased risk of
      bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose
      aspirin daily for at least 10 years. In addition, a meta-analysis reported that long-term
      aspirin use was associated with reduced the risk of gastrointestinal cancers including
      colorectal cancer, esophageal cancer, and gastric cancer.However, most studies that reported
      the cancer prevention effect of long-term aspirin use were conducted as the secondary
      analysis or subgroup analysis of primary studies investigating the aspirin use for
      cardiovascular disease prevention. Thus, there is a limitation that appropriate sample sizes
      and follow-up periods for the cancer prevention effect of aspirin were not considered. In
      2018, we reported that H. pylori treatment reduced the development of metachronous gastric
      cancer after endoscopic resection in early gastric cancer patients. However, metachronous
      gastric cancer could develop after successful H. pylori eradication with an annual incidence
      of 1%-3%. Therefore, we designed a multi-center, double-blind, randomized, placebo-controlled
      trial to evaluate whether long-term low-dose (100 mg) aspirin uses prevents gastric cancer in
      early gastric cancer patients without H. pylori infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of gastric cancer between the intervention and placebo groups</measure>
    <time_frame>Until last enrolled patients take 5-year trial medication</time_frame>
    <description>Histologically confirmed gastric cancer detected at follow-up endoscopy or registered at the Korean Cancer Registry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Until last enrolled patients take 5-year trial medication</time_frame>
    <description>Mortality from any causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of cardiovascular disease and cerebrovascular disease between the intervention and placebo groups</measure>
    <time_frame>Until last enrolled patients take 5-year trial medication</time_frame>
    <description>Cardiovascular diseases (stable and unstable angina, myocardial infarction); Cerebrovascular diseases (transient ischemic attack, cerebral infarction, other small vascular infarction, etc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of other organ cancers between the intervention and placebo groups</measure>
    <time_frame>Until last enrolled patients take 5-year trial medication</time_frame>
    <description>Cancers detected at follow-up visits or registered at the Korean Cancer Registry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of gastric dysplasia (adenoma) between the intervention and placebo groups</measure>
    <time_frame>Until last enrolled patients take 5-year trial medication</time_frame>
    <description>Histologically confirmed gastric dysplasia (adenoma) detected at follow-up endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication related to the aspirin use</measure>
    <time_frame>Until last enrolled patients take 5-year trial medication</time_frame>
    <description>Gastrointestinal bleeding, intracranial hemorrhage, subarachnoid hemorrhage, and other bleeding complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of atrophy and intestinal metaplasia</measure>
    <time_frame>At the time of 5-year trial medication</time_frame>
    <description>Change in histologic atrophy and intestinal metaplasia grades from enrollment to subsequent endoscopic assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>Aspirin</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enteric coated aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Enteric coated aspirin placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 100mg</intervention_name>
    <description>Daily aspirin 100 mg for 5 years</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Daily placebo for 5 years</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 19-70 who underwent endoscopic resection for early gastric cancer

          -  Final pathological results after endoscopic resection met the absolute or expanded
             criteria according to the Japanese Gastric Cancer Treatment guideline 2014 (version 4)

          -  Patients who had negative H. pylori status or those who eradicated H. pylori status

          -  Willingness to sign an informed consent form

        Exclusion Criteria:

          -  Pateints who received aspirin for the secondary prevention of cardiovascular diseases
             or cerebrovascular diseases

          -  Regular aspirin uses (more than 3 times a week) with 2 months before screening visit

          -  Patients who used anticoagulants or antiplatelet drugs for therapeutic purpose

          -  Previous gastrectomy history

          -  Current treatment for serious medical condition which could hinder participation (such
             as severe heart dysfunction, liver cirrhosis, renal failure, COPD or bronchial asthma,
             or uncontrolled infection)

          -  High risk patients for bleeding complications (cerebral aneurysm, vascular
             malformation, esophageal or gastric varices, or hemophilia, etc)

          -  Active peptic ulcer disease (patients who treated peptic ulcer completely could be
             enrolled)

          -  Diagnosis and active treatment for other organ cancer (except carcinoma in situ, and
             non-melanoma skin cancer) within 5 years

          -  Non-curative resection of early gastric cancer after endoscopic resection

          -  Aspirin allergy or contraindication of aspirin use

          -  Pregnant or lactating women

          -  Alcoholism, drug abuse

          -  Inadequte patients for study enrollment according to the evaluation of the study
             physician

          -  Inability to provide an informed consent

          -  Patients who took a 28-day run-in-period medication less than 80%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
    <phone>+82-31-920-2282</phone>
    <email>cij1224@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young-Il Kim, MD</last_name>
    <phone>+82-31-920-1712</phone>
    <email>11996@ncc.re.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwang Ha Kim, M.D., Ph.D.</last_name>
      <email>doc0224@pusan.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49267</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moo In Park, M.D., Ph.D.</last_name>
      <email>gimipark2003@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Chuncheon</city>
        <zip>24253</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwang Ho Baik, M.D.,Ph.D</last_name>
      <email>baikgh@hallym.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chilgok Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong Woo Jeon, M.D., Ph.D.</last_name>
      <email>sw-jeon@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
      <email>cij1224@ncc.re.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seon-Young Park, M.D., Ph.D.</last_name>
      <email>drpsy@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Incheon St.Mary's Hospital/The Catholic University</name>
      <address>
        <city>Incheon</city>
        <zip>21431</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Wook Kim, M.D., Ph.D.</last_name>
      <email>gastro@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Gyu Kim, M.D., Ph.D.</last_name>
      <email>jgkimd@cau.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ji Won Kim, M.D.,Ph.D.</last_name>
      <email>kjwjor@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Il Ju Choi</investigator_full_name>
    <investigator_title>Gastroenterologist</investigator_title>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>Gastric cancer prevention</keyword>
  <keyword>Endoscopic submucosal dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

